国家纳米科学中心孟幻

andan

孟幻，国家纳米科学中心研究员，博士生导师。毕业于北京大学和中国科学院研究生院，获药学专业学士和生物无机化学专业博士学位。毕业后，赴美国加州大学洛杉矶分校（UCLA）从事科研工作，在David Geffen医学院、加州纳米系统研究所（CNSI）、JCCC综合癌症中心（Jonsson Comprehensive Cancer Center）任博士后、助理教授和副教授等职。孟幻研究员长期开展纳米药学、药物递送、纳米生物界面和纳米安全性研究，先后在Nature Communications、PNAS、Science Bulletin、ACS Nano、JACS、Advanced Science、Journal of Clinical Investigation、Accounts of Chemical Research、Advanced Materials、Biomaterials等学术期刊发表SCI论文90余篇，引用约15000余次， h因子51，曾被科睿唯安（Clarivate）认定为全球高引科学家（交叉科学类）。以课题负责人身份，承担国内外研究课题十余项，长期担任几十种学术期刊的审稿人、国内外基金评审人，并拥有多项专利，并进入转化阶段。

姓    名:孟幻       
性    别:男
职    务:无       
职    称:研究员
通讯地址:北京市海淀区中关村北一条11号
邮政编码:100190       
电子邮件:无       

研究领域：
纳米药学、智能纳米药物递送、纳米生物效应和纳米安全性等。

代表论著：       
全部论文列表：https://scholar.google.com/citations?user=JSDANEQAAAAJ&hl=en
近５年代表论文 (2016-2021)：　
· X Liu, J Jiang, Y Liao, I Tang, E Zheng, W Qiu, Mw Lin, X Wang, Y Ji, K Mei, Q Liu, C Hyun Chang, Z A. Wainberg, AE. Nel, H Meng, Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier plus Anti-PD-1, Advanced Science, 2021, in press.  
· X Liu, J Jiang, C Chan, Y Liao, J J. Lodico, I Tang, E Zheng, W Qiu, M Lin, X Wang, Y Ji, K Mei, A E. Nel and H Meng, Development of facile and versatile platinum drug delivering silicasome nanocarriers for efficient pancreatic cancer chemo-immunotherapy, Small, 2021, in press.   
· Y Ji, X Liu, J Li, X Xie, M Huang, J Jiang, YP Liao, T Donahue, H Meng, Use of Ratiometrically Designed Nanocarrier Targeting CDK4/6 And Autophagy Pathways for Effective Pancreatic Cancer Treatment, Nature Communications, 2020, 11, 4249  
· X Liu, I Tang, Z A. Wainberg and H Meng, Safety Considerations of Cancer Nanomedicine – A Key Step Towards Translation, Small, 2020, 2000673.  
· KC Mei, YP Liao, J Jiang, M Chiang, M Khazaieli, X Liu, X Wang, Q Liu, CH Chang, X Zhang, J Li, Y Ji, B Melano, D Telesca, T Xia, H Meng, AE Nel, Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-Immunotherapy in Multiple Solid Tumors, ACS Nano, 2020, 14, 13343–13366  
· X Liu, J Jiang, H Meng, Transcytosis – An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery, Theranostics, doi:10.7150/thno.38587; 2019, 9: 8018–8025  
· X Liu, J Jiang, R Chan, Y Ji, J Lu, YP Liao, M Okene, J Lin, P Lin, CH Chang, X Wang, I Tang, E Zheng, W Qiu, ZA. Wainberg, AE. Nel, and H Meng, Improved Efficacy and Reduced Toxicity Using a Custom-Designed Irinotecan-Delivering Silicasome for Orthotopic Colon Cancer, ACS Nano, 2019, 13, 38-53
· Y Ji, X Liu, M Huang, J Jiang, YP Liao, Q Liu, CH Chang, H Liao, J Lu, X Wang, SM Spencer, H Meng, Development of self-assembled multi-arm polyrotaxanes nanocarriers for systemic plasmid delivery in vivo. Biomaterials, 2019, 192, 416-428
· M R. Emami, C S. Young, Y Ji, X Liu, AD. Pyle, H Meng, and M J. Spencer, Polyrotaxane nanocarriers can deliver CRISPR/Cas9 plasmid to dystrophic muscle cells to successfully edit the DMD gene, Advanced Therapeutics, 2019, 2, 1900061
· X Liu, P Lin, I Perrett, J Lin, Y Liao, CH Chang, J Jiang, N Wu, T Donahue, Z Wainberg, A Nel, and H Meng, Tumor-Penetrating Peptide Enhances Transcytosis of Silicasome-based Chemotherapy for Pancreatic Cancer, The Journal of Clinical Investigation, 2017, 127, 2007–2018
· H Meng, W Leong, K W. Leong, C Chen, YL Zhao, Walking the line: The fate of nanomaterials at biological barriers, Biomaterials, 2018, 174, 41–53 (review paper)
· H Meng, A Nel, Use of Nano Engineered Approaches to Overcome the Stromal Barrier in Pancreas Cancer, Advanced Drug Delivery Review, 2018, 130, 50-57 (review paper)   
· X Liu, A Situ, Y Kang, K Villabroza, Y Liao, C H Chang, T Donahue, A E Nel, and H Meng, Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Show Improved Efficacy and Safety over Liposomes for Pancreatic Cancer, ACS Nano, 2016, 10, 2702–2715